drugset / Trial / NCT00531050

Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol

NCT00531050

Phase 2 Completed 27 enrolled Novartis
RandomizedCrossoverDouble-blindTreatment

Summary

This study investigated the effect of exercise and high-dose salbutamol on the maximum heart rate in patients with chronic obstructive pulmonary disease (COPD) receiving therapeutic doses of indacaterol, salmeterol and placebo.

Timeline

Start
2007-08
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 300 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled